Cian Healthcare Ltd

Cian Healthcare Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Cian Healthcare Ltd

₹ 9.55 4.95%
14 Jul - close price
cian.co BSE - SME: 542678
About

Incorporated in 2003, Cian Healthcare Ltd is engaged in manufacturing and marketing of pharmaceutical products.[1]

Key Points

Business Overview:[1][2]
CHI is a fully integrated pharmaceutical company dealing in gynecology, hematinic, cardio-diabetic, orthopedic, pediatric, derma-cosmetic, antibiotic, CNS, vitamins & nutrient products.

Website BSE
  • Market Cap ₹ 23.9 Cr.
  • Current Price ₹ 9.55
  • High / Low ₹ 9.55 / 3.11
  • Stock P/E
  • Book Value ₹ 8.24
  • Dividend Yield 0.00 %
  • ROCE -12.7 %
  • ROE -24.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Stock is trading at 1.16 times its book value
  • Promoter holding has increased by 67.9% over last quarter.

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -17.1% over past five years.
  • Company has a low return on equity of -10.2% over last 3 years.
  • Company might be capitalizing the interest cost
  • Working capital days have increased from -147 days to 80.2 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Sep 2020 Mar 2021 Sep 2021 Mar 2022 Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025 Mar 2026
28 39 34 37 27 35 33 31 28 19 12 11 17
23 34 29 36 24 32 28 28 23 19 15 15 20
Operating Profit 4 5 5 1 3 3 5 2 5 -0 -3 -4 -3
OPM % 16% 12% 14% 4% 13% 9% 16% 7% 18% -0% -24% -33% -16%
1 -0 0 0 0 0 0 1 0 -12 -0 1 -13
Interest 3 3 3 3 2 2 2 2 2 2 0 0 0
Depreciation 1 1 1 1 1 2 2 2 2 2 1 1 1
Profit before tax 1 1 0 -2 0 -1 2 -1 1 -16 -4 -4 -17
Tax % 12% 35% 140% -0% -48% 22% 7% -23% 0% -0% 2% 0%
1 0 -0 -2 0 -0 1 -1 1 -16 -4 -4 -17
EPS in Rs 0.48 0.16 -0.02 -1.01 0.04 -0.11 0.54 -0.49 0.57 -6.21 -1.66 -1.68 -6.73
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
31 47 52 66 62 57 72 64 68 59 31 28
26 39 42 53 55 49 63 59 58 51 34 35
Operating Profit 5 8 10 13 8 8 10 5 9 8 -3 -6
OPM % 16% 16% 20% 20% 13% 14% 13% 8% 13% 13% -9% -23%
0 0 0 0 1 1 0 0 1 1 -12 -12
Interest 1 4 5 6 6 6 6 5 5 5 2 0
Depreciation 1 2 2 2 2 2 2 3 4 4 3 2
Profit before tax 3 2 3 5 1 0 1 -2 1 0 -20 -21
Tax % 32% 29% 25% 24% 31% 188% 51% -4% 10% -3,800% -0% 1%
2 2 2 4 1 -0 0 -2 1 0 -20 -21
EPS in Rs 186.00 110.71 165.00 285.71 0.38 -0.03 0.14 -0.91 0.43 0.16 -7.87 -8.41
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -5%
5 Years: -17%
3 Years: -25%
TTM: -8%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -5%
Stock Price CAGR
10 Years: %
5 Years: -15%
3 Years: -28%
1 Year: 171%
Return on Equity
10 Years: -2%
5 Years: -6%
3 Years: -10%
Last Year: -25%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 1 1 1 1 17 23 23 25 25 25 25 25
Reserves 7 10 12 16 5 36 37 35 36 37 17 -4
32 31 40 50 49 51 49 43 43 41 40 14
6 15 8 8 22 24 25 36 36 40 61 14
Total Liabilities 46 57 61 77 92 135 135 140 141 143 143 48
19 18 21 20 23 21 19 33 29 26 23 22
CWIP 5 5 4 7 6 25 26 13 14 15 15 6
Investments 0 0 0 0 0 7 7 7 7 7 7 2
22 33 36 50 62 82 83 87 90 95 97 18
Total Assets 46 57 61 77 92 135 135 140 141 143 143 48

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 10 6 8 13 -9 5 6 2 7 21 20
0 -5 -4 -3 -8 -25 -1 -4 -1 -1 -0 13
0 -5 -2 -6 -3 35 -5 -3 -1 -6 -3 -50
Net Cash Flow 0 0 0 -0 2 1 -1 -1 -0 -0 17 -17
Free Cash Flow 0 9 3 5 7 -35 4 2 1 6 20 29
CFO/OP 0% 138% 63% 60% 162% -120% 57% 109% 24% 92% -710% -318%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 116 95 97 142 130 128 93 104 127 114 184 118
Inventory Days 159 137 128 160 144 214 219 325 310 404 461 74
Days Payable 71 122 21 53 144 174 151 275 211 270 609 64
Cash Conversion Cycle 204 111 204 249 130 168 162 154 227 248 35 128
Working Capital Days 52 17 40 56 44 5 12 61 49 49 -571 80
ROCE % 14% 15% 17% 18% 9% 7% 7% 3% 6% 5% -6% -13%

Insights

In beta
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Permanent Employees on Rolls
count

Log in to view insights

Please log in to see hidden values.

Login
Export Revenue Share
%
Production Volume
units
Third Party / Contract Manufacturing Share of Revenue
%
Number of Brands Marketed
count
Number of Manufacturing Facilities
count
Number of Molecules Registered
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Sep 2022Dec 2022Mar 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Sep 2025Mar 2026
66.26% 66.26% 66.26% 66.26% 51.85% 49.62% 27.10% 27.10% 27.11% 27.11% 27.11% 95.00%
0.00% 0.00% 0.00% 0.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
33.74% 33.74% 33.75% 32.96% 48.16% 50.39% 72.90% 72.90% 72.90% 72.89% 72.89% 5.00%
No. of Shareholders 3963924244184546728808311,0881,5011,6621,683

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings